ABVC BioPharma, Inc.
ABVC BioPharma, Inc. (Nasdaq: ABVC) is an early-stage biotechnology company developing botanical drug candidates for central nervous system and cancer conditions, as well as a medical device for eye surgery. Its pipeline includes candidates for major depressive disorder, ADHD, depression in cancer patients, blood and… From the company’s description.
Over the twelve months to Jun 30, 2026, ABVC BioPharma, Inc. reported a net loss of $7.60M. Operations used $2.69M in cash. In fiscal 2025, it reported a net loss of $8.38M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ABVC BioPharma, Inc. does
In the company’s own words
ABVC BioPharma, Inc. (Nasdaq: ABVC) is an early-stage biotechnology company developing botanical drug candidates for central nervous system and cancer conditions, as well as a medical device for eye surgery. Its pipeline includes candidates for major depressive disorder, ADHD, depression in cancer patients, blood and solid-tumor cancers, and Vitargus®, a vitreous substitute used in vitrectomy surgery. The company licenses technologies from research institutions and develops them with clinical investigators and partners, aiming to outlicense or partner its candidates for later-stage development and commercialization. It also earns revenue from intellectual-property outlicenses and contract development and manufacturing services through BioKey, which provides drug development, analytical testing, and clinical-trial and commercial manufacturing. BioKey manufactures dietary supplements, including maitake mushroom tablets and drinks. ABVC’s subsidiaries include BriVision, BioLite, and BioKey; its drug-development operations and manufacturing activities span North America and Asia. For the fiscal year ended December 31, 2025, revenue comes from outlicensing intellectual property and CDMO services. Its website is www.abvbiopharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FREMONT, CA
- Fiscal year end
- December
- CIK
- 1173313
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ABVC BioPharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ABVC BioPharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ABVC BioPharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ABVC BioPharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ABVC BioPharma, Inc.'s last four quarterly filings that the numbers alone won't show?”